跳至主要内容

The Study of Drug Reproductive Toxicity Test

 Medicine.jpg

Medicine is a double-edged sword. It can not only cure diseases and save people but also produce adverse reactions that damage human health.

Reproductive toxicity research is one of the essential contents of drug toxicity research, which refers to the damage of drugs to reproductive function and ability and the unfavorable mailbox for offspring. For drugs to be used in humans, animal reproductive toxicity tests need to be comprehensively considered based on the intended indications and characteristics of the test substance.

We boast professional teams and practical experience in drug safety evaluation and can promise high-quality data and fast turnaround time to support various drug safety evaluation. Our toxicology research can be carried out according to non-GLP or GLP standards. Our research platform has been rated as Shanghai R&D Public Service Platform.

Failure of a compound at the Clinical stage is very costly, and considerable efforts are made to eliminate potentially toxic compounds much earlier in the drug discovery process using in vitro, or even in silico methods.

Understanding the reproductive toxicity of drugs is very important for guiding the safety of the clinical medication. The reproductive toxicity of drugs has two characteristics: sensitivity to the toxic effects of drugs at a specific dose, before damage to other systems, occurs, a particular part of the reproductive process may have been damaged; the reproductive toxicity of drugs is not only manifested in the exposure of drugs The body itself can also affect offspring. Therefore, reproductive toxicity can occur both during pregnancy and during pregnancy and lactation. The drug reproductive toxicity test should implement GLP specifications. There are many research methods for the reproductive and developmental toxicity of drugs. Commonly used reproductive toxicity test programs include the following three parts of joint research:

The Study of Drug Reproductive Toxicity Test

(1) Segment Ⅰ (fertility and early embryo development):

Also called the general reproductive toxicity test studies the effects of drugs on the entire reproductive process. It evaluates whether germ cells adversely affect conception ability, reproductive system, and offspring after drug exposure. At least one animal is used in selecting experimental animals, and rats are the first choice. Fertility and early embryo developmental toxicity tests are an essential part of drug reproductive toxicity research, and they are also indispensable in developing innovative drugs. The staff of Medicilon's reproductive toxicity research service platform is composed of a professional technical team led by senior domestic reproductive toxicity experts with 30 years of research experience; the animal laboratory was jointly established by Medicilon and MPI Research (American Toxicology Research Company), Passed the International Laboratory Animal Assessment and Approval (AAALAC) and reached the GLP dual standards of FDA and CFDA.

(2) Segment Ⅱ (embryo-fetal development):

The purpose is to assess the harmful effects of exposure to the test substance from the blastocyst implantation to the closure of the hard palate (the organogenesis period) on pregnant females and the development of the embryo-fetal body. The consequences of embryo-fetal developmental toxicity are relatively more severe, and we should pay more attention to the results of this test section. If a variety of animals are used for testing, it may provide an adequate test basis when the test results are extrapolated to humans. The test usually uses two animals, one is a rodent, and rats are recommended, and the other is a non-rodent, and rabbits are recommended.

(3) Segment Ⅲ (developmental toxicity test before and after birth)

Perinatal toxicity test to evaluate the effects of drugs on the growth and development of fetuses after birth, to detect the adverse effects of drug administration on pregnant/lactating females, and the development of embryos and offspring from embryo implantation to pup weaning. At least one animal is used in the selection of experimental animals, and rats recommend.

My country's reproductive toxicity research of innovative drugs adopts the conventional three-stage test design. The current reproductive toxicity test research of drugs divides into the above three-stage. When adopting the segmented test design, pay attention to the animal's adulthood from conception to pregnancy. The pups are administered at all stages of sexual maturity. The observation should continue for a complete life cycle (from the beginning of one generation to the next). In actual operation, a single (entire course) test design and a two-stage test design can be used for rodents according to the test substance's indications and characteristics.

In the study of reproductive drug toxicity, other test schemes can also be considered comprehensively according to the characteristics of the test substance, intended indications, and clinical medication.

评论

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

  In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...

What is Toxicokinetics?

Toxicokinetics  is essentially the study of “how a substance gets into the body and what happens to it in the body”. Four processes are involved in toxicokinetics. The study of the kinetics (movement) of chemicals was originally conducted with pharmaceuticals and thus the term pharmacokinetics became commonly used. In addition, toxicology studies were initially conducted with drugs. However, the science of toxicology has evolved to include environmental and occupational chemicals as well as drugs. Toxicokinetics is thus the appropriate term for the study of the kinetics of all toxic substances. Frequently the terms  toxicokinetics ,  pharmacokinetics , or disposition may be found in the literature to have the same meaning. Disposition is often used in place of toxicokinetics to describe the time-course of movement of chemicals through the body (that is, how does the body dispose of a xenobiotic?). The disposition of a toxicant along with its’ biological reactivi...